FibroBiologics Reveals $4 Million Registered Direct Offering Priced According to Nasdaq Regulations

Funding Announcement: FibroBiologics has entered a definitive agreement to issue and sell 3,540,000 shares of common stock and pre-funded warrants to an existing shareholder, with a total expected gross proceeds of approximately $4 million.

Payment Method: The purchase price will be paid using sovereign-issued .9999 fine gold coins, valued at $4,069.18 per ounce, which the company plans to liquidate into U.S. dollars.

Warrants and Stockholder Approval: In a concurrent private placement, unregistered warrants will be issued, allowing the purchase of additional shares, contingent upon stockholder approval, with an exercise price of $0.3303 per share.

Company Overview: FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents in various clinical pathways.